PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 8 Issue 1

Breast Cancer Treatment

Christina Rahm*

July 21, 2026

DOI : 10.56831/PSSRP-08-284

View PDF

Abstract

Breast cancer is one of the most prevalent and biologically complex malignancies worldwide, requiring treatment strategies that extend beyond tumor eradication to account for individual patient variability and the potential toxicities associated with therapy. Surgery, radiotherapy, chemotherapy, endocrine therapy, targeted agents, and immunotherapy have made a lot of improvements to the survival rates of various subtypes of breast cancer. Nevertheless, these treatments are often linked to systemic side effects, immunosuppression, metabolic imbalance, and reduced quality of life. The necessity to maintain patient resilience in the context of extended treatment courses has become more evident as the survival rates are increasing. Adjunctive therapies that regulate tumor-promoting biological pathways with an augmentation of treatment tolerance can hence be found in integrative oncology. This white paper will look at a patented proprietary formulation/treatment protocol that was designed as an adjunctive therapy in the case of breast cancer. The method involves the use of five synchronized formulations made of natural bioactive compounds, micronutrients, prebiotics, and phytochemicals, and applied using a structured, time-based dosing schedule.  The patented technique is based on emerging scientific data on modulation of inflammation, regulation of oxidative stress, immune support, metabolic optimization, and gut-tumor axis interactions. Instead of presenting its invention as a curative intervention, it is specifically made to be used with the known oncologic therapies. It aims at sustaining physiological systems that are mostly suppressed in the normal course of cancer treatment. This paper discusses the scientific reason, mechanical plausibility, formulation synergy, and clinical relevance of the patented strategy.

References

  1. Arnone AA., et al. “Gut microbiota interact with breast cancer therapeutics to modulate efficacy”. EMBO Molecular Medicine 17.2 (2025): 219-234.
  2. Bodai BI and Nakata TE. “Breast cancer: lifestyle, the human gut microbiota/microbiome, and survivorship”. The Permanente Journal 24 (2020): 19-129.
  3. Bose C., et al. “Breast cancer and microbiome: a systematic review highlighting challenges for clinical translation”. BMC women's health 25.1 (2025): 416.
  4. Chen XY., et al. “Dietary index for gut microbiota, genetic risk, and incidence of breast cancer: a prospective study”. Breast Cancer Research 27.1 (2025): 175.
  5. Dong R., et al. “Role of oxidative stress in the occurrence, development, and treatment of breast cancer”. Antioxidants 14.1 (2025): 104.
  6. Duggan C., et al. “Dietary index for gut microbiota, genetic risk, and incidence of breast cancer: a prospective study”. Breast Cancer Research (2025).
  7. Fan Z., et al. “Association between a dietary index for gut microbiota and breast cancer history in adult women: findings from NHANES 2011–2020”. Frontiers in Nutrition 12 (2025): 1619809.
  8. Forma A., et al. “Micronutrient status and breast cancer: a narrative review”. International Journal of Molecular Sciences 25.9 (2024): 4968.
  9. Gamba G., et al. “Gut microbiota and breast cancer: systematic review and meta-analysis”. Breast Cancer 32.2 (2025): 242-257.
  10. Herrera-Quintana L, Vázquez-Lorente H and Plaza-Diaz J. “Breast cancer: extracellular matrix and microbiome interactions”. International Journal of Molecular Sciences 25.13 (2024): 7226.
  11. Jiang Y and Li Y. “Nutrition intervention and microbiome modulation in the Management of Breast Cancer”. Nutrients 16.16 (2024): 2644.
  12. Mokbel K and Mokbel K. “Harnessing micronutrient power: vitamins, antioxidants, and probiotics in breast cancer prevention”. Anticancer Research 44.6 (2024): 2287-2295.
  13. Munteanu C, Mârza SM and Papuc I. “The immunomodulatory effects of vitamins in cancer”. Frontiers in immunology 15 (2024): 1464329.
  14. Neagoe CXR., et al. “The Influence of microbiota on breast cancer: A review”. Cancers 16.20 (2024): 3468.
  15. Scafuri L., et al. “Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review”. Nutrients 17.6 (2025): 981.
  16. Sun L, Fang K and Yang Z. “Combination therapy with probiotics and anti-PD-L1 antibody synergistically ameliorates sepsis in a mouse model”. Heliyon 10.11 (2024).
  17. Thu MS., et al. “Effect of probiotics in breast cancer: a systematic review and meta-analysis”. Biology 12.2 (2023): 280.
  18. Vitorino M., et al. “Human microbiota and immunotherapy in breast cancer: a review of recent developments”. Frontiers in Oncology 11 (2022):  815772.
  19. Wang J., et al. “The Impact of Microbiome on Breast Cancer and Regulatory Strategies”. Microorganisms (2026).
  20. Westerman, R., et al. “Oxidative stress in breast cancer”. Frontiers in Oncology 15 (2025): 1661039.
  21. Wolf CP., et al. “Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine, and other supplements”. Journal of Cancer Research and Clinical Oncology 148.2 (2022): 461-473.
  22. Zhang J, Xia Y and Sun J. “Breast and gut microbiome in health and cancer”. Genes & Diseases 8.5 (2021): 581-589.